TNF receptors: signaling pathways and contribution to renal dysfunction.

[1]  T. Fujimura,et al.  Role of the TNF pathway in the progression of diabetic nephropathy in KK-A(y) mice. , 2014, American journal of physiology. Renal physiology.

[2]  T. Adachi,et al.  Renal atrophy after ischemia–reperfusion injury depends on massive tubular apoptosis induced by TNFα in the later phase , 2014, Medical Molecular Morphology.

[3]  Jiahuai Han,et al.  Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death , 2013, Cell Research.

[4]  Ling-gang Wu,et al.  Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis , 2013, Nature Cell Biology.

[5]  A. Strasser,et al.  The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. , 2013, Immunity.

[6]  M. Lindenmeyer,et al.  Distinct Contributions of TNF Receptor 1 and 2 to TNF-Induced Glomerular Inflammation in Mice , 2013, PloS one.

[7]  M. Mahmoud,et al.  Tumor necrosis factor-alfa and monocyte chemoattractant protein-1 gene polymorphisms in kidney transplant recipients. , 2013, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.

[8]  Y. Gorgi,et al.  Cytokine gene polymorphisms in kidney transplantation. , 2013, Transplantation proceedings.

[9]  Yuzhi Zhang,et al.  Endothelial TNF receptor 2 induces IRF1 transcription factor-dependent interferon-β autocrine signaling to promote monocyte recruitment. , 2013, Immunity.

[10]  S. Cuzzocrea,et al.  The renal injury and inflammation caused by ischemia-reperfusion are reduced by genetic inhibition of TNF-αR1: a comparison with infliximab treatment. , 2013, European journal of pharmacology.

[11]  R. Zwiech.  Predictive Value of Conjointly Examined IL-1ra, TNF-R I, TNF-R II, and RANTES in Patients with Primary Glomerulonephritis , 2013, Journal of Korean medical science.

[12]  C. Benedict,et al.  Clinical targeting of the TNF and TNFR superfamilies , 2013, Nature Reviews Drug Discovery.

[13]  V. Tesar,et al.  Serum cytokine profile in patients with active lupus nephritis. , 2012, Cytokine.

[14]  M. Madaio,et al.  Anti-tumor necrosis factor α treatment of interferon-α-induced murine lupus nephritis reduces the renal macrophage response but does not alter glomerular immune complex formation. , 2012, Arthritis and rheumatism.

[15]  J. Fernández-Real,et al.  Structural damage in diabetic nephropathy is associated with TNF-α system activity , 2012, Acta Diabetologica.

[16]  Tai‐Lung Cha,et al.  TNF-α Induces Epithelial–Mesenchymal Transition of Renal Cell Carcinoma Cells via a GSK3β-Dependent Mechanism , 2012, Molecular Cancer Research.

[17]  D. Bolignano.  [TNF-alpha receptors (TNFRS): the biomarkers of progressive diabetic nephropathy we were waiting for?]. , 2012, Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia.

[18]  N. Kambham.  Crescentic Glomerulonephritis: An Update on Pauci-immune and Anti-GBM Diseases , 2012, Advances in anatomic pathology.

[19]  M. Aringer,et al.  Therapeutic blockade of TNF in patients with SLE-promising or crazy? , 2012, Autoimmunity reviews.

[20]  T. Mayadas,et al.  Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. , 2012, Journal of the American Society of Nephrology : JASN.

[21]  B. Banas,et al.  Elevated urinary sVCAM-1, IL6, sIL6R and TNFR1 concentrations indicate acute kidney transplant rejection in the first 2 weeks after transplantation. , 2012, Cytokine.

[22]  T. Mayadas,et al.  Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. , 2012, Journal of the American Society of Nephrology : JASN.

[23]  G. Miglio,et al.  Angiotensin II induces tumor necrosis factor-α expression and release from cultured human podocytes , 2012, Inflammation Research.

[24]  L. Hlatky,et al.  BREAKING THE “HARMONY” OF TNF-α SIGNALING FOR CANCER TREATMENT , 2011, Oncogene.

[25]  Xin Chen,et al.  Contrasting effects of TNF and anti‐TNF on the activation of effector T cells and regulatory T cells in autoimmunity , 2011, FEBS letters.

[26]  R. Zager,et al.  Acute unilateral ischemic renal injury induces progressive renal inflammation, lipid accumulation, histone modification, and "end-stage" kidney disease. , 2011, American journal of physiology. Renal physiology.

[27]  G. Espinosa,et al.  Epidemiology and management of refractory lupus nephritis. , 2011, Autoimmunity reviews.

[28]  Sheng‐Tang Wu,et al.  Tumor necrosis factor-α induces epithelial–mesenchymal transition of renal cell carcinoma cells via a nuclear factor kappa B-independent mechanism , 2011, Experimental biology and medicine.

[29]  K. Zeng,et al.  Donor or recipient TNF-A -308G/A polymorphism and acute rejection of renal allograft: A meta-analysis. , 2011, Transplant immunology.

[30]  K. Morino,et al.  Association between serum soluble TNFα receptors and renal dysfunction in type 2 diabetic patients without proteinuria. , 2011, Diabetes research and clinical practice.

[31]  W. Fodor,et al.  Identification of soluble and membrane‐bound isoforms of porcine tumor necrosis factor receptor 2 , 2011, Xenotransplantation.

[32]  C. Ware,et al.  TNF Receptor-1 Is Required for the Formation of Splenic Compartments during Adult, but Not Embryonic Life , 2011, The Journal of Immunology.

[33]  P. Nelson,et al.  TNFR2 interposes the proliferative and NF-κB-mediated inflammatory response by podocytes to TNF-α , 2010, Laboratory Investigation.

[34]  S. Czekalski,et al.  Urinary excretion of soluble tumour necrosis factor receptor 1 as a marker of increased risk of progressive kidney function deterioration in patients with primary chronic glomerulonephritis. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[35]  G. Conte,et al.  Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[36]  J. Bradley,et al.  The Role of Tumor Necrosis Factor-α Converting Enzyme in Renal Transplant Rejection , 2010, American Journal of Nephrology.

[37]  J. Larkin,et al.  A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma , 2010, British Journal of Cancer.

[38]  I. Mills,et al.  Tumor necrosis factor receptor expression and signaling in renal cell carcinoma. , 2010, The American journal of pathology.

[39]  K. Lai,et al.  Cytokines and Their Roles in the Pathogenesis of Systemic Lupus Erythematosus: From Basics to Recent Advances , 2010, Journal of biomedicine & biotechnology.

[40]  T. Vanden Berghe,et al.  The Role of the Kinases RIP1 and RIP3 in TNF-Induced Necrosis , 2010, Science Signaling.

[41]  B. Lim,et al.  Pretreatment with the tumor nerosis factor-alpha blocker etanercept attenuated ischemia-reperfusion renal injury. , 2009, Transplantation proceedings.

[42]  Gyanendra Kumar Sonkar,et al.  Evaluation of serum tumor necrosis factor alpha and its correlation with histology in chronic kidney disease, stable renal transplant and rejection cases. , 2009, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.

[43]  C. Gordon,et al.  Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. , 2009, Rheumatology.

[44]  J. Ishii,et al.  Expression of Tumor Necrosis Factor Receptors on Granulocytes in Patients with Myeloperoxidase Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis , 2009, Nephron Clinical Practice.

[45]  T. Mayadas,et al.  Immunoregulatory role of TNFalpha in inflammatory kidney diseases. , 2009, Kidney international.

[46]  T. Chiba,et al.  Modulation of the Th1/Th2 balance by infliximab improves hyperthyroidism associated with a flare-up of ulcerative colitis. , 2009, Inflammatory bowel diseases.

[47]  C. Edwards,et al.  Anti-TNF-induced lupus. , 2009, Rheumatology.

[48]  T. Sugiyama,et al.  Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients. , 2009, Clinical and experimental rheumatology.

[49]  C. Pace,et al.  Upregulation of TNF Receptor Type 2 in Human and Experimental Renal Allograft Rejection , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[50]  J. Navarro-González,et al.  Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy. , 2009, Cytokine & growth factor reviews.

[51]  S. Zheng,et al.  Accelerated Pathological and Clinical Nephritis in Systemic Lupus Erythematosus-Prone New Zealand Mixed 2328 Mice Doubly Deficient in TNF Receptor 1 and TNF Receptor 2 via a Th17-Associated Pathway1 , 2009, The Journal of Immunology.

[52]  M. Abecassis,et al.  Intragraft TNF Receptor Signaling Contributes to Activation of Innate and Adaptive Immunity in a Renal Allograft Model , 2009, Transplantation.

[53]  I. Hatamura,et al.  TNF-alpha deficiency accelerates renal tubular interstitial fibrosis in the late stage of ureteral obstruction. , 2008, Experimental and molecular pathology.

[54]  Jordan S. Pober,et al.  Endothelial Cells in Allograft Rejection , 2008, Transplantation.

[55]  M. Aringer,et al.  A Bridge Between Interferon-α and Tumor Necrosis Factor in Lupus , 2008 .

[56]  M. Deng,et al.  Tumor‐derived tumor necrosis factor‐alpha promotes progression and epithelial‐mesenchymal transition in renal cell carcinoma cells , 2008, Cancer science.

[57]  B. Aggarwal,et al.  TNF: a master switch for inflammation to cancer. , 2008, Frontiers in bioscience : a journal and virtual library.

[58]  C. Charbonneau,et al.  Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. , 2008, Cancer treatment reviews.

[59]  W. Min,et al.  TL1A both promotes and protects from renal inflammation and injury. , 2008, Journal of the American Society of Nephrology : JASN.

[60]  Rama Devi Mittal,et al.  Analysis of cytokine gene polymorphisms in recipient’s matched with living donors on acute rejection after renal transplantation , 2008, Molecular and Cellular Biochemistry.

[61]  L. Ivashkiv,et al.  TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon–response genes , 2008, Nature Immunology.

[62]  M. Ivanova,et al.  Cytokine gene polymorphism in kidney transplantation — Impact of TGF-β1, TNF-α and IL-6 on graft outcome , 2008 .

[63]  M. Aringer,et al.  The role of tumor necrosis factor-alpha in systemic lupus erythematosus , 2008, Arthritis research & therapy.

[64]  Chandra Mohan,et al.  Elevated Urinary VCAM-1, P-Selectin, Soluble TNF Receptor-1, and CXC Chemokine Ligand 16 in Multiple Murine Lupus Strains and Human Lupus Nephritis1 , 2007, The Journal of Immunology.

[65]  M. Gore,et al.  Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  Y. Moriwaki,et al.  Effect of TNF-α inhibition on urinary albumin excretion in experimental diabetic rats , 2007, Acta Diabetologica.

[67]  Stephen L. Abrams,et al.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. , 2007, Biochimica et biophysica acta.

[68]  G. Ramesh,et al.  Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. , 2007, Kidney international.

[69]  M. M. Ahmed,et al.  Isolated renal sarcoidosis: a rare presentation of a rare disease treated with infliximab , 2007, Clinical Rheumatology.

[70]  G. Dong,et al.  Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. , 2007, Biochemical pharmacology.

[71]  E. Mazzon,et al.  Splanchnic ischemia and reperfusion injury is reduced by genetic or pharmacological inhibition of TNF‐α , 2007, Journal of leukocyte biology.

[72]  K. Meldrum,et al.  TNF-α neutralization ameliorates obstruction-induced renal fibrosis and dysfunction , 2007 .

[73]  S. Uppal,et al.  Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus , 2007, Modern rheumatology.

[74]  K. Nath,et al.  Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia-reperfusion injury. , 2007, Kidney international.

[75]  N. Maisey.  Antitumor Necrosis Factor (TNF-a) Antibodies in the Treatment of Renal Cell Cancer , 2007, Cancer investigation.

[76]  B. Mayer,et al.  Gene expression and biomarkers in renal transplant ischemia reperfusion injury , 2007, Transplant international : official journal of the European Society for Organ Transplantation.

[77]  B. Geramizadeh,et al.  Cytokine gene polymorphisms in renal transplant recipients. , 2006, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[78]  S. Sánchez-Ramón,et al.  Efficacy and safety of Etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy , 2006, Lupus.

[79]  B. Aggarwal,et al.  Inflammation and cancer: how hot is the link? , 2006, Biochemical pharmacology.

[80]  F. Balkwill.  TNF-α in promotion and progression of cancer , 2006, Cancer and Metastasis Reviews.

[81]  P. Heeringa,et al.  TNF-alpha bioactivity-inhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[82]  R. Zager,et al.  Acute renal failure: determinants and characteristics of the injury-induced hyperinflammatory response. , 2006, American journal of physiology. Renal physiology.

[83]  L. Klareskog,et al.  Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital , 2005 .

[84]  R. Balshaw,et al.  Immune Response Gene Polymorphisms in Renal Transplant Recipients , 2005, Transplantation.

[85]  S. Nourshargh,et al.  Therapeutic effect of anti-TNF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. , 2005, Journal of the American Society of Nephrology : JASN.

[86]  P. Vandenabeele,et al.  TNFR1‐ and TNFR2‐mediated signaling pathways in human kidney are cell type‐specific and differentially contribute to renal injury , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[87]  T. Kita,et al.  Clinical Efficacy of Intravenous Immunoglobulin for Patients with MPO-ANCA-Associated Rapidly Progressive Glomerulonephritis , 2005, Nephron Clinical Practice.

[88]  R. Brink,et al.  Tumor Necrosis Factor Receptor 2 (TNFR2) Signaling Is Negatively Regulated by a Novel, Carboxyl-terminal TNFR-associated Factor 2 (TRAF2)-binding Site* , 2005, Journal of Biological Chemistry.

[89]  R. Zager,et al.  Ischemic proximal tubular injury primes mice to endotoxin-induced TNF-alpha generation and systemic release. , 2005, American journal of physiology. Renal physiology.

[90]  V. D’Agati,et al.  Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis , 2005 .

[91]  P. Heeringa,et al.  Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. , 2005, The American journal of pathology.

[92]  T. Mayadas,et al.  Renal cell-expressed TNF receptor 2, not receptor 1, is essential for the development of glomerulonephritis. , 2005, The Journal of clinical investigation.

[93]  S. Marshall,et al.  Cytokine polymorphisms do not influence acute rejection in renal transplantation under tacrolimus-based immunosuppression. , 2005, Transplantation proceedings.

[94]  C. Pusey,et al.  Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis. , 2005, Kidney international.

[95]  H. Oral,et al.  Cytokine gene polymorphisms as potential risk and protective factors in renal cell carcinoma. , 2005, Cytokine.

[96]  R. Moots,et al.  Anti-TNF-α therapies: they are all the same (aren't they?) , 2005 .

[97]  X. Mariette,et al.  Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey , 2005, Arthritis research & therapy.

[98]  P. Rosenstiel,et al.  The Met-196 → Arg Variation of Human Tumor Necrosis Factor Receptor 2 (TNFR2) Affects TNF-α-induced Apoptosis by Impaired NF-κB Signaling and Target Gene Expression* , 2005, Journal of Biological Chemistry.

[99]  T. Horiuchi,et al.  Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. , 2005, Gastroenterology.

[100]  R. A. Mahmoud,et al.  Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus. , 2005, Clinical biochemistry.

[101]  K. Meldrum,et al.  TNF-α mediates obstruction-induced renal tubular cell apoptosis and proapoptotic signaling , 2005 .

[102]  M. Aringer,et al.  Cytokine expression in lupus kidneys , 2005, Lupus.

[103]  S. Targan,et al.  Safety and Efficacy of Adalimumab (D2E7) in Crohn's Disease Patients with an Attenuated Response to Infliximab , 2005, The American Journal of Gastroenterology.

[104]  Silvia Kirchner,et al.  Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. , 2004, Cytokine.

[105]  A. Kirk,et al.  Donor genomics influence graft events: the effect of donor polymorphisms on acute rejection and chronic allograft nephropathy. , 2004, Kidney international.

[106]  M. Aringer,et al.  Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. , 2004, Arthritis and rheumatism.

[107]  G. Ramesh,et al.  Inflammatory cytokines in acute renal failure. , 2004, Kidney international. Supplement.

[108]  S. Ghosh,et al.  Signaling to NF-kappaB. , 2004, Genes & development.

[109]  Somasekar Seshagiri,et al.  De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling , 2004, Nature.

[110]  J. Medina-Pestana,et al.  IMPACT OF CREATININE AFTER REJECTION ON RENAL ALLOGRAFT SURVIVAL , 2004 .

[111]  L. Padyukov,et al.  Impaired Kidney Graft Survival is Associated with the TNF-&agr; Genotype , 2004, Transplantation.

[112]  M. Crow,et al.  Regulation of c-Jun N-terminal kinase and p38 kinase pathways in endothelial cells. , 2004, American journal of respiratory cell and molecular biology.

[113]  W. Min,et al.  Thioredoxin-2 Inhibits Mitochondria-Located ASK1-Mediated Apoptosis in a JNK-Independent Manner , 2004, Circulation research.

[114]  Patrick Dowd,et al.  The ubiquitin ligase COP1 is a critical negative regulator of p53 , 2004, Nature.

[115]  R. Schwabe,et al.  Differential requirement for c‐Jun NH2‐terminal kinase in TNF‐α‐and Fas‐mediated apoptosis in hepatocytes , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[116]  S. Marangi,et al.  Lupus Nephritis Improvement After Anti‐tumor Necrosis Factor Alpha Monoclonal Antibody (Infliximab) Treatment for Crohn's Disease: A Case Report , 2004, Immunopharmacology and immunotoxicology.

[117]  W. Min,et al.  Etk/Bmx Transactivates Vascular Endothelial Growth Factor 2 and Recruits Phosphatidylinositol 3-Kinase to Mediate the Tumor Necrosis Factor-induced Angiogenic Pathway* , 2003, Journal of Biological Chemistry.

[118]  R. Panettieri,et al.  Tumor Necrosis Factor α Modulates Airway Smooth Muscle Function via the Autocrine Action of Interferon β* , 2003, Journal of Biological Chemistry.

[119]  K. Sugimura,et al.  Effects of tumor necrosis factor α in renal cell carcinoma , 2003 .

[120]  M. Ohh,et al.  The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway. , 2003, Cancer research.

[121]  G. Ramesh,et al.  TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. , 2003, American journal of physiology. Renal physiology.

[122]  S. Nedospasov,et al.  Dissecting the role of lymphotoxin in lymphoid organs by conditional targeting , 2003, Immunological reviews.

[123]  J. Dahlerup,et al.  The effect of etanercept and infliximab on the production of tumour necrosis factor α, interferon-γ and GM-CSF in in vivo activated intestinal T lymphocyte cultures , 2003 .

[124]  O. Micheau.  Cellular FLICE-inhibitory protein: an attractive therapeutic target? , 2003, Expert opinion on therapeutic targets.

[125]  T. Ninomiya,et al.  Antioxidant ameliorates cisplatin-induced renal tubular cell death through inhibition of death receptor-mediated pathways. , 2003, American journal of physiology. Renal physiology.

[126]  J. Navarro,et al.  Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[127]  J. Tschopp,et al.  Induction of TNF Receptor I-Mediated Apoptosis via Two Sequential Signaling Complexes , 2003, Cell.

[128]  D. Hommes,et al.  Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. , 2003, Gastroenterology.

[129]  M. Gorospe,et al.  von Hippel-Lindau Protein-Mediated Repression of Tumor Necrosis Factor Alpha Translation Revealed through Use of cDNA Arrays , 2003, Molecular and Cellular Biology.

[130]  R. Rau.  Adalimumab (a fully human anti-tumour necrosis factor α monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials , 2002, Annals of the rheumatic diseases.

[131]  W. Min,et al.  Etk/Bmx as a Tumor Necrosis Factor Receptor Type 2-Specific Kinase: Role in Endothelial Cell Migration and Angiogenesis , 2002, Molecular and Cellular Biology.

[132]  G. Ramesh,et al.  TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity , 2002 .

[133]  N. Senninger,et al.  sTNF‐RII: is it useful for the early diagnosis of rejection and for prognosis after renal transplantation? , 2002, Transplant international : official journal of the European Society for Organ Transplantation.

[134]  L. Kamesh,et al.  ANCA-positive vasculitis. , 2002, Journal of the American Society of Nephrology : JASN.

[135]  T. Mak,et al.  Signaling for survival and apoptosis in the immune system , 2002, Arthritis research.

[136]  M. Sherman,et al.  Hsp72 and Stress Kinase c-jun N-Terminal Kinase Regulate the Bid-Dependent Pathway in Tumor Necrosis Factor-Induced Apoptosis , 2002, Molecular and Cellular Biology.

[137]  Xiao-Yu Song,et al.  Binding and functional comparisons of two types of tumor necrosis factor antagonists. , 2002, The Journal of pharmacology and experimental therapeutics.

[138]  H. Ichijo,et al.  Activation of apoptosis signal‐regulating kinase 1 by the stress‐induced activating phosphorylation of pre‐formed oligomer , 2002, Journal of cellular physiology.

[139]  M. Aringer,et al.  Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death , 2002, Lupus.

[140]  M. Gorospe,et al.  Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNFα cytotoxicity , 2002, Oncogene.

[141]  V. Tesar,et al.  Soluble cytokine receptors in renal vasculitis and lupus nephritis. , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[142]  K. Haley,et al.  Prolonged Allograft Survival in TNF Receptor 1-Deficient Recipients Is Due to Immunoregulatory Effects, Not to Inhibition of Direct Antigraft Cytotoxicity1 , 2002, The Journal of Immunology.

[143]  J. Skepper,et al.  Expression of Tumor Necrosis Factor Receptors in Normal Kidney and Rejecting Renal Transplants , 2001, Laboratory Investigation.

[144]  K. Tokunaga,et al.  Analysis of the association of HLA-DRB1, TNFα promoter and TNFR2 (TNFRSF1B) polymorphisms with SLE using transmission disequilibrium test , 2001, Genes and Immunity.

[145]  J. Tschopp,et al.  NF-κB Signals Induce the Expression of c-FLIP , 2001, Molecular and Cellular Biology.

[146]  Xianglin Shi,et al.  New Insights into the Role of Nuclear Factor-κB in Cell Growth Regulation , 2001 .

[147]  S. Takasawa,et al.  Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. , 2001, The Journal of clinical investigation.

[148]  C. Pusey,et al.  Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor-alpha. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[149]  M. Feldmann,et al.  Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. , 2000, Arthritis and rheumatism.

[150]  L. Truong,et al.  Mechanism of chronic obstructive uropathy: increased expression of apoptosis-promoting molecules. , 2000, Kidney international.

[151]  J. Weening,et al.  Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. , 2000, Journal of the American Society of Nephrology : JASN.

[152]  W. B. Reeves,et al.  Transforming growth factor β contributes to progressive diabetic nephropathy , 2000 .

[153]  A. Karsan,et al.  A1 Functions at the Mitochondria to Delay Endothelial Apoptosis in Response to Tumor Necrosis Factor* , 2000, The Journal of Biological Chemistry.

[154]  Joni K. Evans,et al.  Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[155]  B. Seed,et al.  Regulated commitment of TNF receptor signaling: a molecular switch for death or activation. , 1999, Immunity.

[156]  S. Klahr,et al.  Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. , 1999, American journal of physiology. Renal physiology.

[157]  G. Kovacs.  Molecular genetics and diagnosis of renal cell tumors , 1999, Der Urologe.

[158]  J. Pober,et al.  Recent advances in the molecular basis of TNF signal transduction. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[159]  Paul,et al.  Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. , 1999, Kidney international.

[160]  K. Tokunaga,et al.  Association of tumor necrosis factor receptor 2 (TNFR2) polymorphism with susceptibility to systemic lupus erythematosus. , 1999, Tissue antigens.

[161]  M. Macía,et al.  Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure. , 1999, Scandinavian journal of urology and nephrology.

[162]  D. Goeddel,et al.  Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. , 1999, Science.

[163]  C. Johnston,et al.  Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. , 1998, Circulation.

[164]  B. Ryffel,et al.  Prevention of crescentic glomerulonephritis induced by anti-glomerular membrane antibody in tumor necrosis factor-deficient mice. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[165]  D. Lebwohl,et al.  Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. , 1998, European journal of cancer.

[166]  W. Schultze‐Seemann,et al.  Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid. , 1998, Anticancer research.

[167]  H. Kung,et al.  Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[168]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[169]  Stefan Grimm,et al.  The Death Domain Kinase RIP Mediates the TNF-Induced NF-κB Signal , 1998 .

[170]  J. Pober.  Activation and injury of endothelial cells by cytokines. , 1998, Pathologie-biologie.

[171]  M. Sabatine,et al.  Delayed rejection of soluble tumor necrosis factor receptor-secreting tumor allografts. , 1998, Transplantation.

[172]  V. Tesar,et al.  Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[173]  M. Cobb,et al.  Mitogen-activated protein kinase pathways. , 1997, Current opinion in cell biology.

[174]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[175]  T. Vischer,et al.  Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. , 1997, The Journal of rheumatology.

[176]  L. Owen-Schaub,et al.  Human Tumor Necrosis Factor Receptor p75/80 (CD120b) Gene Structure and Promoter Characterization* , 1996, The Journal of Biological Chemistry.

[177]  D. Goeddel,et al.  Anatomy of TRAF2 , 1996, The Journal of Biological Chemistry.

[178]  S. Klahr,et al.  The expression of mRNA for tumour necrosis factor‐α increases in the obstructed kidney of rats soon after unilateral ureteral ligation , 1996 .

[179]  B. Ryffel,et al.  Differentiation of follicular dendritic cells and full antibody responses require tumor necrosis factor receptor-1 signaling , 1996, The Journal of experimental medicine.

[180]  G. Strassmann,et al.  Mutational analysis of TNF-alpha gene reveals a regulatory role for the 3'-untranslated region in the genetic predisposition to lupus-like autoimmune disease. , 1996, Journal of immunology.

[181]  M. Karin.  The regulation of AP-1 activity by mitogen-activated protein kinases. , 1996, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[182]  Hong-Bing Shu,et al.  TRADD–TRAF2 and TRADD–FADD Interactions Define Two Distinct TNF Receptor 1 Signal Transduction Pathways , 1996, Cell.

[183]  Mike Rothe,et al.  The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins , 1995, Cell.

[184]  I. Tikkanen,et al.  Increased renal expression of cytokines and growth factors induced by DOCA-NaCl treatment in Heymann nephritis. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[185]  W. Fiers,et al.  Dimerization of chimeric erythropoietin/75 kDa tumour necrosis factor (TNF) receptors transduces TNF signals: necessity for the 75 kDa-TNF receptor transmembrane domain. , 1995, Cytokine.

[186]  D. Malide,et al.  Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. , 1995, Human pathology.

[187]  D. Goeddel,et al.  Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice , 1994, Nature.

[188]  C. Maass,et al.  THE EXTENT OF PERITUBULAR CD14 STAINING IN RENAL ALLOGRAFTS AS AN INDEPENDENT IMMUNOHISTOLOGICAL MARKER FOR ACUTE REJECTION , 1994, Transplantation.

[189]  D. Goeddel,et al.  A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor , 1994, Cell.

[190]  B. Escalante,et al.  TNF production by the medullary thick ascending limb of Henle's loop. , 1994, Kidney international.

[191]  K. Tokunaga,et al.  Tumor necrosis factor-alpha mRNA expression in lipopolysaccharide-stimulated rat kidney. Chronological analysis of localization. , 1994, The American journal of pathology.

[192]  T. Kita,et al.  The immunocytochemical localization of tumour necrosis factor and leukotriene in the rat kidney after treatment with lipopolysaccharide. , 1993, International journal of experimental pathology.

[193]  L. Tartaglia,et al.  Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. , 1993, The Journal of biological chemistry.

[194]  E. Ritz,et al.  In situ production of TNF-α, IL-1β and IL-2R in ANCA-positive glomerulonephritis , 1993 .

[195]  David L. Brautigan,et al.  Raf-1 activates MAP kinase-kinase , 1992, Nature.

[196]  L. Moldawer,et al.  Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[197]  D. Wallach,et al.  Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors , 1992, The Journal of experimental medicine.

[198]  C. Jacob,et al.  Tumor necrosis factor alpha in murine systemic lupus erythematosus disease models: implications for genetic predisposition and immune regulation. , 1991, Cytokine.

[199]  R. Berger,et al.  The gene for the type II (p75) tumor necrosis factor receptor (TNF-RII) is localized on band 1p36.2–p36.3 , 1991, Human Genetics.

[200]  P. Tipping,et al.  Tumor necrosis factor production by glomerular macrophages in anti-glomerular basement membrane glomerulonephritis in rabbits. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[201]  W. Fiers.  Tumor necrosis factor Characterization at the molecular, cellular and in vivo level , 1991, FEBS letters.

[202]  P. McLaughlin,et al.  EVALUATION OF SEQUENTIAL PLASMA AND URINARY TUMOR NECROSIS FACTOR ALPHA LEVELS IN RENAL ALLOGRAFT RECIPIENTS , 1991, Transplantation.

[203]  P. McLaughlin,et al.  Tumour necrosis factor in renal transplantation. , 1991, Transplantation proceedings.

[204]  H. Loetscher,et al.  Purification and partial amino acid sequence analysis of two distinct tumor necrosis factor receptors from HL60 cells. , 1990, The Journal of biological chemistry.

[205]  R. Gentz,et al.  Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. , 1990, Cytokine.

[206]  H. Schoenfeld,et al.  Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[207]  D. Brennan,et al.  Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. , 1989, Journal of immunology.

[208]  T. Taniguchi,et al.  Induction of the transcription factor IRF-1 and interferon-beta mRNAs by cytokines and activators of second-messenger pathways. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[209]  A. Rees,et al.  Modulation of antibody-mediated glomerular injury in vivo by bacterial lipopolysaccharide, tumor necrosis factor, and IL-1. , 1989, Journal of immunology.

[210]  J. Oudinet,et al.  Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide. , 1989, Kidney international.

[211]  N. Perico,et al.  Tumor necrosis factor induces glomerular damage in the rabbit. , 1989, The American journal of pathology.

[212]  J. M. Boswell,et al.  Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. , 1988, Journal of immunology.

[213]  C. Jacob,et al.  Tumour necrosis factor-α in murine autoimmune 'lupus' nephritis , 1988, Nature.

[214]  W. Buurman,et al.  Interferon beta 1, an intermediate in the tumor necrosis factor alpha- induced increased MHC class I expression and an autocrine regulator of the constitutive MHC class I expression , 1987, The Journal of experimental medicine.

[215]  C. Maury,et al.  Raised serum levels of cachectin/tumor necrosis factor alpha in renal allograft rejection , 1987, The Journal of experimental medicine.

[216]  T. Decker,et al.  Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. , 1987, Journal of immunology.

[217]  L. Old,et al.  Tumor necrosis factor (TNF). , 1985, Science.

[218]  B. Trump,et al.  Cis-Diamminedichloroplatinum (II)-induced Acute Renal Failure in the Rat: Enzyme Histochemical Studies , 1985, Toxicologic pathology.

[219]  B. Reeves,et al.  The chromosome changes in non-Burkitt lymphomas , 1980, Human Genetics.

[220]  Shao-Cong Sun,et al.  Non-canonical NF-κB signaling pathway , 2011, Cell Research.

[221]  M. Kitagawa,et al.  Decrease in Tumor Necrosis Factor- (cid:1) Receptor-Associated Death Domain Results from Ubiquitin-Dependent Degradation in Obstructive Renal Injury in Rats , 2009 .

[222]  J. Stone.  Etanercept plus Standard Therapy for Wegener's Granulomatosis , 2005 .

[223]  U. Helmchen,et al.  Crescentic glomerulonephritis associated with myeloperoxidase-antineutrophil-cytoplasmic antibodies: first report on the efficacy of primary anti-TNF-alpha treatment. , 2004, International journal of tissue reactions.

[224]  F. Gesek,et al.  Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. , 2003, American journal of physiology. Renal physiology.

[225]  J. Bonventre,et al.  Pathophysiology of ischemic acute renal failure. , 2001, Contributions to nephrology.

[226]  K. Sugimura,et al.  TNF alpha, IL-1 beta and IL-6 production by peripheral blood monocytes in patients with renal cell carcinoma. , 2000, Anticancer research.

[227]  J. Mcgiff,et al.  Angiotensin II induces TNF production by the thick ascending limb: functional implications. , 1998, American journal of physiology. Renal physiology.

[228]  M. Paller,et al.  Nitric oxide-mediated renal epithelial cell injury during hypoxia and reoxygenation. , 1998, Renal failure.

[229]  A. Baldwin,et al.  THE NF-κB AND IκB PROTEINS: New Discoveries and Insights , 1996 .

[230]  J. Pober,et al.  Disparate localization of 55-kd and 75-kd tumor necrosis factor receptors in human endothelial cells. , 1995, The American journal of pathology.

[231]  M. Grell.  Tumor necrosis factor (TNF) receptors in cellular signaling of soluble and membrane-expressed TNF. , 1995, Journal of inflammation.

[232]  F. Stockenhuber,et al.  Value of serum soluble tumour necrosis factor concentrations in the diagnosis and prognosis of renal graft rejection. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[233]  J. Gogusev,et al.  [Expression of IL6 and TNF-alpha in normal and pathological kidney]. , 1993, Comptes rendus des seances de la Societe de biologie et de ses filiales.

[234]  P. Vassalli,et al.  The pathophysiology of tumor necrosis factors. , 1992, Annual review of immunology.

[235]  K. Olthoff,et al.  The role of tumor necrosis factor in allograft rejection. III. Evidence that anti-TNF antibody therapy prolongs allograft survival in rats with acute rejection. , 1991, Transplantation.

[236]  P. Tipping,et al.  J Am Soc Nephrol 14: 1785–1793, 2003 Intrinsic Renal Cells Are the Major Source of Tumor Necrosis Factor Contributing to Renal Injury in Murine Crescentic , 2022 .